Don’t use the ‘C

A patient named William, a 53-year-old with a demanding lifestyle, received a cancer diagnosis of prostate cancer following a routine health exam. The article explores the dissonance between the public perception of "cancer" and its modern biological understanding, particularly concerning screening practices and terminology. The author contrasts the visceral impact of a diagnosis with contemporary medical practice, noting that while many diagnoses pose little immediate threat to life, they carry significant psychological, social, and economic consequences for patients.
The essay delves into the evolution of understanding cancer, moving from viewing it as the failure of a single body system to understanding it as a cellular process involving uncontrolled growth and evolution driven by accumulated genetic mutations. The author argues that the term "cancer," while culturally potent, often obscures the biological reality, especially regarding low-grade tumors that may not threaten survival but still prompt unnecessary treatment.
The core tension revolves around overdiagnosis stemming from widespread screening practices, such as PSA testing, which leads to overtreatment and adverse side effects for many patients. The essay suggests a need to reevaluate the language used in medicine and reconsider the threshold for diagnosis, advocating for a focus on active surveillance rather than immediate, aggressive treatment for lesions that do not pose an immediate threat to life.

* William was 53 years old when he received a cancer diagnosis.
* His cancer was in his prostate.
* The biopsy revealed a prostate tumor designated 'grade group 1', showing few molecular hallmarks of cancer and no immediate potential for metastasis or death.
* William smoked for the first time in decades before seeking treatment.
* Cancer kills over 600,000 people in the United States annually.
* Medical practices often use adjectives like 'low-grade' and 'low-risk' to manage patient anxiety.
* Screening methods included Pap smears (cervical cancer), mammography/colonoscopy (breast/colon cancer), and Prostate-Specific Antigen (PSA) testing for prostate cancer.
* Widespread screening led to overdiagnosis, where lesions that would never cause symptoms were detected.
* The US Preventive Services Task Force recommended against routine PSA-based screening in 2012.
* Low-grade prostate cancer is exceedingly common and may be a feature of normal male aging.
* Incidentalomas, such as finding abnormalities during scans for unrelated conditions, have entered clinical vernacular.
* Some lesions, like Ductal carcinoma in situ of the breast and certain thyroid lesions, are being reclassified due to lack of invasive behavior.

The narrative critiques the persistence of a binary linguistic structure—"normal" versus "cancer"—that remains deeply entrenched despite advances in molecular biology. The pattern observed is that as scientific understanding deepens concerning the complexity of carcinogenesis and the role of benign cellular variation, the medical lexicon lags behind, allowing cultural resonance rooted in historical fear to dictate clinical action, often leading to harm through overdiagnosis and overtreatment. This manifests as a failure to reconcile biological reality with lived patient experience.
The argument pivots on the distinction between lesions that truly threaten survival (the "lions") and those that are benign cellular variations or precursor states (the "kittens"). The structural vulnerability lies in the inability of current systems, and the language they employ, to effectively differentiate these categories without resorting to labeling with potentially harmful terms. This dynamic is exacerbated by the shift from symptom-driven diagnosis to molecular detection via screening, which often flags low-grade findings as potential threats.
The proposed solution involves dismantling the necessity for a binary label in all cases, advocating for a continuum of terminology that acknowledges the molecular reality—that cellular changes exist across a spectrum—while simultaneously recognizing the functional difference between truly malignant spread and indolent growth. The system is currently structured to prioritize public reassurance (avoiding panic) over accurate risk stratification for every cell change.
Bridge Questions: How can clinical systems effectively integrate evolving molecular data with enduring cultural narratives regarding disease? What concrete mechanisms are needed to re-calibrate the threshold for intervention when distinguishing between true threats and benign variations becomes more nuanced at the cellular level? If labeling changes, what is the ethical responsibility of the physician in managing patient fear generated by a diagnosis that may ultimately be overdiagnosed?